Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Turning Point Therapeutics, Inc. - Common stock (NQ: TPTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Turning Point Therapeutics, Inc. - Common stock

< Previous 1 2 Next >
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
From Bristol Myers Squibb
Via Business Wire
Blue Chip Stocks In Focus: Bristol-Myers Squibb
The company has grown earnings by more than 20% per year on average over the last five and ten years. This explosive growth has enabled the company to continue growing its dividend. 
Via Talk Markets
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Analyst Ratings for Turning Point
Within the last quarter, Turning Point (NASDAQ:TPTX) has observed the following analyst ratings: 
Via Benzinga
Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate
Via Benzinga
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter. 
Via Benzinga
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into. 
Via InvestorPlace
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
From Kahn Swick & Foti, LLC
Via Business Wire
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up
Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out. 
Via Investor's Business Daily
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VMW, TPTX, CTT, CTEK
NEW YORK, NY / ACCESSWIRE / June 9, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or... 
From Halper Sadeh LLP
Via AccessWire
10 Biggest Price Target Changes For Monday
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday. 
Via Benzinga
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
From Kahn Swick & Foti, LLC
Via Business Wire
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
The Acquisition of Turning Point Therapeutics By BMY- Bristol- Myers.
BMY - Bristol-Myers Squibb in a transaction that values Turning Point Therapeutics (NASDAQ:TPTX). Report at roughly $4.1 billion, Bristol-Myers Squibb 
Via Best Stocks
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
CrowdStrike (CRWD) Stock Dips Despite Earnings Beat
CrowdStrike (CRWD) stock is falling on Friday despite a positive Q1 fiscal 2023 earnings report from the cybersecurity company. 
Via InvestorPlace
TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
Turning Point Therapeutics (TPTX) stock is rocketing higher on Friday following news of a deal with Bristol-Myers Squibb (BMY). 
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday. 
Via Benzinga
Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash — Is The Biotech Bear Dead?
Bristol Myers is moving deeper into the targeted oncology space. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Expert Ratings for Turning Point
Over the past 3 months, 4 analysts have published their opinion on Turning Point (NASDAQ:TPTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
Upgrades 
Via Benzinga
Turning Point Therapeutics Gets FDA Breakthrough Therapy designation For Repotrectinib
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate Repotrectinib in Patients With One... 
Via Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.